Workflow
润都股份(002923) - 2022 Q1 - 季度财报
Rundu PharmaRundu Pharma(SZ:002923)2022-04-19 16:00

Financial Performance - The company's operating revenue for Q1 2022 was CNY 322,719,191.72, a decrease of 0.43% compared to CNY 324,097,123.51 in the same period last year[4] - Net profit attributable to shareholders increased by 8.79% to CNY 38,124,057.71 from CNY 35,043,698.73 year-on-year[4] - The net profit after deducting non-recurring gains and losses rose by 9.38% to CNY 35,417,281.48 compared to CNY 32,378,567.30 in the previous year[4] - Operating profit for the first quarter was CNY 41,577,682.14, a slight increase from CNY 40,093,005.83 in the previous year, reflecting a growth of 3.7%[19] - Total revenue from sales of goods and services reached CNY 264,507,609.83, compared to CNY 230,956,278.36 in the prior year, marking an increase of 14.6%[22] - The net profit for the first quarter of 2022 was CNY 38,124,057.71, representing an increase of 8.0% compared to CNY 35,043,698.73 in the same period last year[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,975,466,545.59, reflecting a growth of 3.46% from CNY 1,909,438,088.21 at the end of the previous year[4] - Total liabilities at the end of the quarter were CNY 825,158,626.37, compared to CNY 797,282,506.70 at the beginning of the year, indicating an increase of approximately 3.5%[16] - The company's total assets increased to CNY 1,975,466,545.59 from CNY 1,909,438,088.21, reflecting a growth of about 3.5%[16] Cash Flow - The company's cash flow from operating activities improved by 17.27%, with a net outflow of CNY 18,417,173.83 compared to CNY 22,262,319.72 in the same period last year[4] - The cash flow from operating activities showed a net outflow of CNY -18,417,173.83, an improvement from CNY -22,262,319.72 in the same quarter last year[23] - The total cash inflow from financing activities was CNY 107,075,340.00, compared to CNY 179,000,000.00 in the previous year, indicating a decrease of 40.1%[24] - Investment activities resulted in a net cash outflow of CNY -115,496,056.70, worsening from CNY -53,766,585.30 in the same quarter last year[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,623[10] - The company reported a basic and diluted earnings per share of CNY 0.21, up from CNY 0.19 in the same quarter last year[20] Operational Metrics - Total operating costs for Q1 2022 were CNY 283,735,560.59, down from CNY 285,260,907.53 in the previous period, indicating a decrease of about 0.5%[18] - The company's cash and cash equivalents at the end of the quarter were CNY 189,090,940.55, down from CNY 250,301,867.27 at the beginning of the year, reflecting a decrease of approximately 24.4%[14] - Accounts receivable increased to CNY 122,144,942.45 from CNY 114,536,538.93, marking an increase of about 6.3%[14] - Inventory levels rose to CNY 380,668,863.94, compared to CNY 335,527,464.40 at the start of the year, representing an increase of approximately 13.4%[14] Borrowings - Long-term borrowings increased by 42.83% to CNY 357,075,340.00, attributed to financing for ongoing projects[8] - The company experienced a 90.91% reduction in short-term borrowings, decreasing to CNY 3,000,000.00 from CNY 33,000,000.00[8] - Short-term borrowings decreased significantly from CNY 33,000,000.00 to CNY 3,000,000.00, a reduction of about 90.9%[15] Research and Development - Research and development expenses increased to CNY 21,615,040.10, up 14.8% from CNY 18,827,629.40 year-over-year[19] Strategic Focus - The company continues to focus on expanding its product offerings and market presence, although specific new products or technologies were not detailed in the report[13]